Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros








Base de dados
Intervalo de ano de publicação
1.
Virology ; 408(1): 1-13, 2010 Dec 05.
Artigo em Inglês | MEDLINE | ID: mdl-20863545

RESUMO

Effective vaccine development for human immunodeficiency virus type 1 (HIV-1) will require assays that ascertain the capacity of vaccine immunogens to elicit neutralizing antibodies (NAb) to diverse HIV-1 strains. To facilitate NAb assessment in peripheral blood mononuclear cell (PBMC)-based assays, we developed an assay-adaptable platform based on a Renilla luciferase (LucR) expressing HIV-1 proviral backbone. LucR was inserted into pNL4-3 DNA, preserving all viral open reading frames. The proviral genome was engineered to facilitate expression of diverse HIV-1 env sequences, allowing analysis in an isogenic background. The resulting Env-IMC-LucR viruses are infectious, and LucR is stably expressed over multiple replications in PBMC. HIV-1 neutralization, targeting TZM-bl cells, was highly correlative comparing virus (LucR) and cell (firefly luciferase) readouts. In PBMC, NAb activity can be analyzed either within a single or multiple cycles of replication. These results represent advancement toward a standardizable PBMC-based neutralization assay for assessing HIV-1 vaccine immunogen efficacy.


Assuntos
Anticorpos Anti-HIV/imunologia , HIV-1/crescimento & desenvolvimento , Leucócitos Mononucleares/virologia , Luciferases de Renilla/biossíntese , Coloração e Rotulagem/métodos , Virologia/métodos , Replicação Viral , Vacinas contra a AIDS/imunologia , Anticorpos Neutralizantes/imunologia , HIV-1/genética , HIV-1/imunologia , Humanos , Luciferases de Renilla/genética , Testes de Neutralização/métodos , Proteínas Recombinantes/biossíntese , Proteínas Recombinantes/genética
2.
J Mol Biol ; 365(5): 1368-78, 2007 Feb 02.
Artigo em Inglês | MEDLINE | ID: mdl-17141805

RESUMO

The HIV-1 p51/p66 reverse transcriptase (RT) heterodimer interface comprises, in part, intermolecular interaction of the loop region between beta-strands 7 and 8 (beta7-beta8 loop) in the p51 fingers subdomain with the p66 palm subdomain. In this study, for the first time in the context of infectious HIV-1 particles, we analyzed the contribution of amino acid residues (S134, I135, N136, N137, T139 and P140) in the beta7-beta8 loop for RT heterodimerization, enzymatic activity, and virus infectivity. Mutating asparagine 136 to alanine (N136A) reduced viral infectivity and enzyme activity dramatically. The N136A mutation appeared to destabilize the RT heterodimer and render both the p66 and p51 subunits susceptible to aberrant cleavage by the viral protease. Subunit-specific mutagenesis demonstrated that the presence of the N136A mutation in the p51 subunit alone was sufficient to cause degradation of RT within the virus particle. Alanine mutation at other residues of the beta7-beta8 loop did not affect either RT stability or virus infectivity significantly. None of the beta7-beta8 loop alanine mutations affected the sensitivity of virus to inhibition by NNRTIs. In the context of infectious virions, our results indicate a critical role of the p51 N136 residue within the beta7-beta8 loop for RT heterodimer stability and function. These findings suggest the interface comprising N136 in p51 and interacting residues in p66 as a possible target for rational drug design.


Assuntos
Aminoácidos/análise , Aminoácidos/metabolismo , Transcriptase Reversa do HIV/química , HIV-1/enzimologia , Replicação Viral/fisiologia , Alanina/genética , Sequência de Aminoácidos , Asparagina/genética , Dimerização , Infecções por HIV/enzimologia , Protease de HIV/metabolismo , Transcriptase Reversa do HIV/genética , HIV-1/patogenicidade , HIV-1/fisiologia , Humanos , Concentração Inibidora 50 , Dados de Sequência Molecular , Mutação/genética , Ligação Proteica/efeitos dos fármacos , Estrutura Secundária de Proteína/efeitos dos fármacos , Subunidades Proteicas/química , Subunidades Proteicas/metabolismo , Inibidores da Transcriptase Reversa/farmacologia , Relação Estrutura-Atividade , Vírion/efeitos dos fármacos , Vírion/enzimologia , Replicação Viral/efeitos dos fármacos
3.
J Virol ; 78(5): 2426-33, 2004 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-14963138

RESUMO

Mutation rates of human immunodeficiency virus type 1 (HIV-1) genomes have been estimated using purified reverse transcriptase or single-round infection system. Since small sequences were used as templates, the overall mutation rates could only be extrapolated and the biological significance of mutations is unknown. For direct estimation of HIV-1 mutation rates and understanding of the potential biological influences of mutations, we obtained 19 complete or nearly full-length proviral genomes from single-round-infected adherent cells of lymphocytes by using a lambda phage library method and a long-range PCR technique. Analysis of 160,000 bp of sequences showed that the overall mutation rate of HIV-1 genomes was 5.4 x 10(-5) per base per replication cycle. On average, 1.1 mutations (range, 0 to 3) were generated in each viral genome during one infection cycle. Inspection of the mutations in the HIV-1 genome revealed that all site mutations within protein-coding regions were nonsynonymous mutations. Among all mutations, half were deleterious (premature stop codon and deletions) and would result in defective genomes. By applying the same system to an HIV-1 genome with a G262A mutation in the thumb region of the reverse transcriptase, a significant increase was observed in deletion and insertion mutation rates but no increase in the overall mutation rate in viral genomes was found.


Assuntos
HIV-1/genética , HIV-1/fisiologia , Mutação/genética , Sequência de Bases , Linhagem Celular , Análise Mutacional de DNA , Genoma Viral , Transcriptase Reversa do HIV/genética , HIV-1/enzimologia , Células HeLa , Humanos , Células Jurkat , Cinética , Linfócitos/virologia , Mutagênese , Deleção de Sequência
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA